Anticalin Platform for Development of Inhaled Therapies in Chronic Airway Disease

Time: 2:00 pm
day: Conference Day 1


  • Bullet points: inhaled Anticalin antagonists for respiratory disease
  • Benefits of local intervention via inhalation versus systemic administration
  • Development of PRS-060, a potential first-in-class, inhaled IL-4Ra inhibitor for the treatment of asthma